reviewTop 1% cited

Hormone replacement therapy and endometrial cancer risk: A meta-analysis

Obstetrics and Gynecology · 1995 · Vol. 85(2) · pp. 304–313

Deb Grady✉(University of California, San Francisco)Tebeb Gebretsadik(Kaiser Permanente)Karla Kerlikowske(San Francisco VA Medical Center)Virginia L. Ernster(University of California, San Francisco)Diana B. Petitti(San Francisco VA Medical Center)

View via DOI Publisher page

Abstract

Endometrial cancer risk increases substantially with long duration of unopposed estrogen use, and this increased risk persists for several years after discontinuation of estrogen. Although not statistically significant, the risk of death from endometrial cancer among unopposed estrogen users is increased, similar to the increased risk of developing the disease. Data regarding risk for endometrial cancer among estrogen plus progestin users are limited and conflicting.

Estrogen and related hormone effects Endometrial and Cervical Cancer Treatments Menopause: Health Impacts and TreatmentsMedicineEndometrial cancerRelative riskEstrogenDiscontinuationGynecologyHormone therapyCohort studyProgestinInternal medicine